Literature DB >> 15853918

Reduced release of intact and cleaved urokinase receptor in stimulated whole-blood cultures from human immunodeficiency virus-1-infected patients.

S R Ostrowski1, T Piironen, G Høyer-Hansen, J Gerstoft, B K Pedersen, H Ullum.   

Abstract

The blood levels of the soluble forms of the urokinase receptor (suPAR) are increased in human immunodeficiency virus (HIV)-1-infected patients. This study investigated whether the release of urokinase-type plasminogen activator receptor (uPAR) in whole-blood cultures was affected by HIV infection. The release of different uPAR forms in whole-blood cultures incubated 24 h with or without phytohemagglutinin and lipopolysaccharide was analysed in 47 HIV patients and 19 controls. suPAR was measured by enzyme-linked immunosorbent assay (ELISA) (bulk-suPAR) and three different time-resolved fluorescence immunoassays measuring three-domain suPAR [suPAR(I-III)], three- and two-domain suPAR [suPAR(I-III) + suPAR(II-III)] and one-domain suPAR [suPAR(I)]. The uPAR release was correlated to leucocyte subpopulations and plasma levels of suPAR. The stimulated net whole-blood culture release of bulk-uPAR, uPAR(I-III), uPAR(II-III) and uPAR(I) was reduced in HIV patients (all P < 0.01), whereas the spontaneous bulk-uPAR and uPAR(I-III) release was increased in HIV patients (both P < 0.05). The stimulated uPAR release in whole-blood cultures correlated well to leucocytes and circulating suPAR levels in controls, whereas the correlation was weaker to leucocytes and nonexisting to circulating suPAR levels in HIV patients. These findings demonstrate that HIV infection affects stimulated and spontaneous uPAR release in whole-blood cultures. Given that high blood levels of suPAR in HIV patients are linked to immune activation, the perturbations in uPAR release in whole-blood cultures from HIV patients may also reflect immune activation.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15853918     DOI: 10.1111/j.1365-3083.2005.01582.x

Source DB:  PubMed          Journal:  Scand J Immunol        ISSN: 0300-9475            Impact factor:   3.487


  4 in total

1.  Expression of the urokinase plasminogen activator receptor (uPAR) and its ligand (uPA) in brain tissues of human immunodeficiency virus patients with opportunistic cerebral diseases.

Authors:  Manuela Nebuloni; Paola Cinque; Nicolai Sidenius; Angelita Ferri; Eleonora Lauri; Elisabetta Omodeo-Zorini; Pietro Zerbi; Luca Vago
Journal:  J Neurovirol       Date:  2008-12-24       Impact factor: 2.643

2.  Cumulative childhood risk is associated with a new measure of chronic inflammation in adulthood.

Authors:  Line Jee Hartmann Rasmussen; Terrie E Moffitt; Jesper Eugen-Olsen; Daniel W Belsky; Andrea Danese; HonaLee Harrington; Renate M Houts; Richie Poulton; Karen Sugden; Benjamin Williams; Avshalom Caspi
Journal:  J Child Psychol Psychiatry       Date:  2018-05-09       Impact factor: 8.982

3.  Utility of the plasma level of suPAR in monitoring risk of mortality during TB treatment.

Authors:  Paulo Rabna; Andreas Andersen; Christian Wejse; Ines Oliveira; Victor Francisco Gomes; Maya Bonde Haaland; Peter Aaby; Jesper Eugen-Olsen
Journal:  PLoS One       Date:  2012-08-28       Impact factor: 3.240

Review 4.  Immune system-related soluble mediators and COVID-19: basic mechanisms and clinical perspectives.

Authors:  Mohammad Sadegh Soltani-Zangbar; Forough Parhizkar; Mojtaba Abdollahi; Navid Shomali; Leili Aghebati-Maleki; Sima Shahmohammadi Farid; Leila Roshangar; Ata Mahmoodpoor; Mehdi Yousefi
Journal:  Cell Commun Signal       Date:  2022-08-29       Impact factor: 7.525

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.